中国经济网北京12月29日讯宏源药业（301246）(301246.SZ)今日收报23.93元，跌幅10.97%。该股目前 处于破发状态。 宏源药业首次公开发行股票募集资金总额为人民币236,286.00万元，扣除发行费用后募集资金净额为 219,584.37万元。该公司最终募集资金净额比原计划多154,511.37万元。宏源药业于2023年3月14日披露 的招股说明书显示，该公司拟募集资金65,073.00万元，用于研发中心及多功能试验车间项目、抗病毒原 料药及中间体项目、年产25亿片(粒)高端制剂车间项目。 宏源药业首次公开发行股票的发行费用总额为16,701.63万元，其中保荐及承销费用13,931.96万元。 宏源药业于2023年3月20日在深交所创业板上市，公开发行股票4,725.72万股，发行价格为50.00元/股， 保荐机构(主承销商)为民生证券股份有限公司(现为国联民生（601456）证券股份有限公司)，保荐代表 人为谢广化、肖继明。 上市首日，宏源药业盘中创下股价高点45元，此后股价震荡下跌。 ...

Group 1 - The lithium battery sector is experiencing significant fluctuations, with companies such as Xinwangda, Hongyuan Pharmaceutical, and Aolian Electronics seeing declines of over 10% [1] - More than ten stocks, including Mofangduo, Tianhua New Energy, Shenzhen New Star, Yongtai Technology, and Huasheng Lithium Battery, have dropped by over 5% [1]

早盘锂电池概念震荡下挫，锂矿、电解液方向领跌，欣旺达、宏源药业跌超10%，多氟多、天华新能、 大中矿业、海科新源、清水源均跌超7%。 ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.49% on December 26, with Sunflower leading the drop [1] - The Shanghai Composite Index closed at 3963.68, up 0.1%, while the Shenzhen Component Index closed at 13603.89, up 0.54% [1] Stock Performance - Notable gainers included: - Hongyuan Pharmaceutical (301246) with a closing price of 26.88, up 20.00% and a trading volume of 476,800 shares, totaling 1.216 billion yuan [1] - Fuxiang Pharmaceutical (300497) closed at 16.08, up 6.70% with a trading volume of 889,200 shares, totaling 1.4 billion yuan [1] - Key stocks with positive performance also included Keyuan Pharmaceutical (301281), Kangzhiyue Pharmaceutical (300086), and Ailisi (688578) [1] - Major decliners included: - Sunflower (300111) with a closing price of 6.36, down 10.80% and a trading volume of 1,429,900 shares, totaling 899 million yuan [2] - Xinnoway (300765) closed at 36.88, down 6.77% with a trading volume of 189,500 shares, totaling 711 million yuan [2] - Other notable declines were seen in Shouyao Holdings (688197) and Kelun Pharmaceutical (002422) [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 1.096 billion yuan from institutional investors, while retail investors contributed a net inflow of 914 million yuan [2] - The capital flow data indicates that: - Hongyuan Pharmaceutical had a net inflow of 230 million yuan from institutional investors, while retail investors had a net outflow of 127 million yuan [3] - Fuxiang Pharmaceutical experienced a net inflow of 178 million yuan from institutional investors, with a net outflow of 140 million yuan from retail investors [3] - Other companies like Shutaishen (300204) and Kangzhiyue (300086) also showed varied capital flows [3]

证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交3.84亿元，其中，买入成交额为2.85亿 元，卖出成交额为9885.73万元，合计净买入1.87亿元。 具体来看，今日上榜的营业部中，共有4家机构专用席位现身，即买四、买五、卖一、卖二、卖三、卖 四，合计买入金额1.10亿元，卖出金额8257.20万元，合计净买入2773.34万元。 宏源药业今日涨停，全天换手率29.79%，成交额12.16亿元，振幅11.95%。龙虎榜数据显示，机构净买 入2773.34万元，营业部席位合计净买入1.59亿元。 深交所公开信息显示，当日该股因日收盘价涨幅达20.00%上榜，机构专用席位净买入2773.34万元。 资金流向方面，今日该股主力资金净流入2.45亿元，其中，特大单净流入3.03亿元，大单资金净流出 5819.97万元。近5日主力资金净流入3.10亿元。 融资融券数据显示，该股最新（12月25日）两融余额为2.97亿元，其中，融资余额为2.96亿元，融券余 额为61.82万元。近5日融资余额合计增加1.34亿元，增幅为82.14%，融券余额合计增加31.64万元，增幅 104.82%。（数据宝） 宏源药业12 ...

Market Overview - The market experienced a high opening followed by a decline, with all three major indices turning negative during the session. The Shanghai and Shenzhen markets saw a half-day trading volume of 1.45 trillion, a significant increase of 251.3 billion compared to the previous trading day. Over 3,900 stocks in the market declined [1] - The Shanghai Composite Index fell by 0.19%, while the Shenzhen Component Index rose by 0.17%, and the ChiNext Index decreased by 0.15% [1] Sector Performance - The lithium battery supply chain showed strong performance, with Tianji Co. achieving three consecutive trading limits in four days, and several other stocks like Hongyuan Pharmaceutical and Yongxing Materials hitting their daily limits [1] - The commercial aerospace sector remained active, with Shenjian Co. achieving seven consecutive trading limits and Jiuding New Materials achieving four consecutive limits [1] - The photovoltaic sector saw partial gains, with stocks like GCL-Poly and Yijing Photovoltaic hitting their daily limits [1] - The Hainan Free Trade Zone concept stocks were also active, with Hainan Development achieving five limits in six days [1] - In contrast, the computing hardware sector showed weakness, with Changguang Huaxin dropping over 10% [1] Lithium Market Insights - The main contract for lithium carbonate surged past 130,000, increasing by over 8% during the day, marking a new high since November 2023. The market outlook for lithium prices remains optimistic due to recovering quarterly earnings from lithium companies and increasing demand from new energy vehicles [3] - The China Nonferrous Metals Industry Association's lithium division indicated that lithium futures prices are expected to gradually rise by November 2025, with increased volatility anticipated [3] Hainan Free Trade Zone Developments - The Hainan Free Trade Port officially commenced its first week of full island closure, with customs reporting over 400 million yuan in "zero tariff" imports and over 20 million yuan in domestic processing goods exempt from tariffs [5] - The duty-free shopping market in Hainan saw a surge, with shopping amounts reaching 1.1 billion yuan and 165,000 shoppers during the week of December 18-24 [5] Photovoltaic Sector Developments - Four leading silicon wafer companies significantly raised their prices on December 25, with average increases reaching 12%. This price hike is attributed to substantial increases in upstream silicon material costs [9][20] Investment Trends - UBS Wealth Management forecasts that the Chinese stock market will continue to have upward potential, driven by advanced manufacturing and technology sectors. The report highlights that AI and technology are key growth drivers, with expectations for significant earnings growth in the Hang Seng Technology Index by 2026 [30] - The National Development and Reform Commission announced that the National Venture Capital Guidance Fund will increase investments in early-stage projects in sectors such as integrated circuits, artificial intelligence, aerospace, and low-altitude economy [31]

Market Overview - The A-share market experienced a sharp pullback after an initial rise, with all three major indices turning negative during the session. The total trading volume in the Shanghai and Shenzhen markets reached 1.45 trillion, a significant increase of 251.3 billion compared to the previous trading day. Over 3,900 stocks in the market declined [1]. Sector Performance - The lithium battery industry chain showed rapid strength, with Tianji Co. achieving three consecutive trading limits in four days. Other stocks such as Hongyuan Pharmaceutical and Yongxing Materials also hit the daily limit [2]. - The commercial aerospace concept remained active, with Shenjian Co. achieving seven consecutive trading limits [2]. - New materials stocks saw four consecutive trading limits, and Jiayuan Technology reached the daily limit. The photovoltaic sector experienced localized gains, with companies like GCL-Poly Energy and Yijing Photovoltaic hitting the daily limit. The Hainan Free Trade Zone concept was also active, with Hainan Development achieving five trading limits in six days [3]. Declining Sectors - The computing hardware concept showed weakness, with Changguang Huaxin dropping over 10%. By the end of the trading session, the Shanghai Composite Index fell by 0.19%, while the Shenzhen Component Index rose by 0.17%, and the ChiNext Index decreased by 0.15% [4].

据天眼查APP显示，湖北省宏源药业科技股份有限公司成立于2002年01月21日，注册资本40000.68万人 民币。（数据宝） （文章来源：证券时报网） 数据宝统计，截至10:42，宏源药业成交额10.22亿元，创上市以来新高。最新股价上涨20.00%，换手率 25.28%。上一交易日该股全天成交额为8.25亿元。 ...

Group 1 - The company is currently developing in line with its annual plan expectations [2] - The company has completed the preparation of kilogram-level sulfide electrolyte precursors and electrolyte samples [2] - The company is conducting testing and optimization for solid-state electrolytes and is preparing for pilot line construction [2]

Group 1 - The company confirms that its development in the pharmaceutical sector, particularly in high-end raw materials and formulations, is in line with the annual planning expectations [2] - The company has completed the preparation of kilogram-level sulfide electrolyte precursors and electrolyte samples, and is currently optimizing testing for solid electrolytes while preparing for pilot line construction [2]